COMPARISON OF SOLIFENACIN VERSUS MIRABEGRON IN WOMEN WITH OVERACTIVE BLADDER PRESENTING AT A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.71000/w0kqhw21Keywords:
Mirabegron, Solifenacin, Adverse effects, Overactive bladder, Pharmacologic therapy, Women’s health, TolerabilityAbstract
Background: Overactive bladder (OAB) is a common and distressing syndrome characterized by urinary urgency, frequency, nocturia, and urgency incontinence in the absence of urinary tract infection or other pathology. It significantly impacts physical comfort, emotional well-being, and social functioning. Pharmacologic management primarily involves antimuscarinic agents and β3-adrenergic receptor agonists, with Mirabegron offering comparable efficacy but a more favorable side-effect profile compared to antimuscarinics.
Objective: To evaluate and compare the therapeutic efficacy and tolerability of Solifenacin and Mirabegron in women with overactive bladder.
Methods: This comparative cross-sectional study was conducted at Chandka Medical Hospital between March and August 2025. A total of 161 female patients aged 18 years and above with OAB symptoms persisting for over three months were enrolled. Group A received Solifenacin 10 mg daily, and Group B received Mirabegron 25 mg daily. The duration of therapy was three weeks, after which symptom improvement was evaluated based on the number of micturition episodes, urgency episodes, and incontinence per 24 hours. Data were analyzed using SPSS version 20, with p < 0.05 considered statistically significant.
Results: The mean age of participants was 41.8 ± 7.56 years. The mean duration of OAB symptoms was 4.6 ± 0.91 months. Baseline mean values included 9.2 ± 2.1 micturitions, 6.6 ± 1.3 urgency episodes, and 5.1 ± 1.51 incontinence episodes per 24 hours. After treatment, Mirabegron showed superior symptom reduction compared to Solifenacin, with significant improvement in nocturia (p < 0.05). Adverse effects such as dry mouth, constipation, and dizziness were more frequent in the Solifenacin group, whereas Mirabegron demonstrated better tolerability and lower discontinuation rates.
Conclusion: Both medications effectively improved OAB symptoms, but Mirabegron offered superior therapeutic benefits with fewer side effects and greater tolerability, making it a preferable choice for managing overactive bladder in women.
References
Zhang Y, Song J, Li B, Wu Y, Jia S, Shu H, et al. Association between body roundness index and overactive bladder: results from the NHANES 2005-2018. Lipids Health Dis. 2024;23(1):184.
Li Z, Liu X, Li Y, Chen X, Liu Z, Gao X, et al. Association between cardiovascular health and overactive bladder. Sci Rep. 2025;15(1):5760.
Zhang K, Tai Y, Gong Y, Zhou Y, Wang C, Shang J. The association between urinary cadmium exposure levels and overactive bladder syndrome in the U.S. adults from NHANES database. Sci Rep. 2025;15(1):12870.
Gong H, Huang S. Associations of overactive bladder (OAB) with suicidal ideation incidence and all-cause mortality among the U.S. population. BMC Psychiatry. 2024;24(1):641.
Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol. 2024;212(1):11-20.
Khan Z, Healey GD, Paravati R, Berry N, Rees E, Margarit L, et al. Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study. Front Cell Infect Microbiol. 2021;11:752275.
Clearwater W, Kassam F, Aalami Harandi A, Tenggardjaja CF, Abraham N. Combination and Novel Pharmacologic Agents for OAB. Curr Urol Rep. 2022;23(7):129-41.
Wada N, Mizunaga M, Abe N, Miyauchi K, Kobayashi S, Ohtani M, et al. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol. 2024;42(1):113.
Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091-107.
Hagovska M, Svihra J, Sr., Macko L, Breza J, Jr., Svihra J, Jr., Luptak J, et al. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World J Urol. 2024;42(1):287.
Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. Ann Phys Rehabil Med. 2022;65(1):101486.
Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022;82(1):49-59.
Al-Dossari R, Kalra M, Adkison J, Nguyen BM. Non-Surgical Management of Urinary Incontinence. J Am Board Fam Med. 2024;37(5):909-18.
Grizelj B, Orešković S, Mikuš M, Banović V, Kalafatić D, Šprem Goldštajn M. Overactive Bladder or Anxiety: Which Came First? Psychiatr Danub. 2021;33(4):485-90.
Zhu S, Wang Z, Tao Z, Wang S, Wang Z. Relationship Between Marijuana Use and Overactive Bladder (OAB): A Cross-Sectional Research of NHANES 2005 to 2018. Am J Med. 2023;136(1):72-8.
Song W, Hu H, Ni J, Zhang H, Zhang Y, Zhang H, et al. The Role of Sarcopenia in Overactive Bladder in Adults in the United States: Retrospective Analysis of NHANES 2011-2018. J Nutr Health Aging. 2023;27(9):734-40.
Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928-33.
Sayner AM, Rogers F, Tran J, Jovanovic E, Henningham L, Nahon I. Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review. Neuromodulation. 2022;25(8):1086-96.
Wang J, Ren L, Liu X, Liu J, Ling Q. Underactive Bladder and Detrusor Underactivity: New Advances and Prospectives. Int J Mol Sci. 2023;24(21).
Galhardo LM, Giorgenon GV, Rótoli M, de Araújo CC, Brito LGO, Juliato CRT. Unilateral and Bilateral Transcutaneous Tibial Nerve Stimulation in Women With Overactive Bladder Syndrome: A Randomized Controlled Study (UBTTNS-OAB Study). Neurourol Urodyn. 2025;44(1):125-35.
Babin CP, Catalano NT, Yancey DM, Pearl NZ, Koonce EM, Ahmadzadeh S, et al. Update on Overactive Bladder Therapeutic Options. Am J Ther. 2024;31(4):e410-e9.
Farag F, Sakalis VI, Arteaga SM, Sihra N, Karavitakis M, Arlandis S, et al. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel. Eur Urol. 2023;84(3):302-12.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: Analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77:119-28
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rashid Ali, Ammanullah Abbasi, Muhammad Imran Soomro, Abdul Hafeez, Muhammad Parial Shahani (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
